Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXGNNASDAQ:DRTSNASDAQ:EMBCNASDAQ:IRMD On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$11.47+1.0%$11.61$7.33▼$21.00$522.34M1.04495,660 shs675,857 shsDRTSAlpha Tau Medical$3.25-1.2%$2.95$1.93▼$4.39$275.67M0.9949,040 shs7,191 shsEMBCEmbecta$10.32+2.9%$10.87$9.20▼$21.48$603.13M1.08497,261 shs200,466 shsIRMDiRadimed$58.94-0.1%$56.56$42.34▼$63.29$749.72M0.9144,191 shs74,533 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen+4.03%+4.70%+4.03%-28.60%+50.66%DRTSAlpha Tau Medical+3.79%+5.45%+8.94%+32.13%+48.87%EMBCEmbecta-2.81%+3.51%+2.45%-12.78%-12.48%IRMDiRadimed-4.54%-1.29%-2.45%+21.27%+34.87%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAXGNAxoGen2.1956 of 5 stars3.52.00.00.00.62.50.6DRTSAlpha Tau Medical1.8744 of 5 stars3.53.00.00.00.61.70.0EMBCEmbecta4.2199 of 5 stars3.21.03.30.00.63.33.8IRMDiRadimed4.3338 of 5 stars2.52.02.54.40.03.31.9Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXGNAxoGen 3.00Buy$24.50113.60% UpsideDRTSAlpha Tau Medical 3.00Buy$8.00146.15% UpsideEMBCEmbecta 2.33Hold$19.3387.34% UpsideIRMDiRadimed 3.00Buy$72.0022.16% UpsideCurrent Analyst Ratings BreakdownLatest DRTS, AXGN, EMBC, and IRMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/23/2025EMBCEmbectaBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingSet Price TargetBuy ➝ Buy$25.005/23/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$15.00 ➝ $13.005/13/2025AXGNAxoGenCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$26.00 ➝ $24.004/29/2025DRTSAlpha Tau MedicalHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$9.00 ➝ $9.004/10/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageNeutral$15.004/9/2025EMBCEmbectaMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeHold(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXGNAxoGen$187.34M2.79N/AN/A$2.36 per share4.86DRTSAlpha Tau MedicalN/AN/AN/AN/A$0.89 per shareN/AEMBCEmbecta$1.08B0.56$3.34 per share3.09($12.80) per share-0.81IRMDiRadimed$73.24M10.24$1.51 per share39.06$6.85 per share8.60Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXGNAxoGen-$9.96M-$0.15N/AN/AN/A-3.68%-7.09%-3.67%8/6/2025 (Estimated)DRTSAlpha Tau Medical-$31.75M-$0.46N/AN/AN/AN/A-49.48%-36.69%8/13/2025 (Estimated)EMBCEmbecta$78.30M$0.9011.473.360.664.89%-19.67%12.27%8/8/2025 (Estimated)IRMDiRadimed$19.23M$1.5538.0329.47N/A26.33%23.28%20.59%7/30/2025 (Estimated)Latest DRTS, AXGN, EMBC, and IRMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/19/2025Q1 2025DRTSAlpha Tau Medical-$0.14-$0.12+$0.02-$0.12$0.03 millionN/A5/9/2025Q2 2025EMBCEmbecta$0.66$0.70+$0.04$0.40$261.77 million$259.00 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXGNAxoGenN/AN/AN/AN/AN/ADRTSAlpha Tau MedicalN/AN/AN/AN/AN/AEMBCEmbecta$0.605.81%N/A66.67%N/AIRMDiRadimed$0.681.15%N/A43.87%1 YearsLatest DRTS, AXGN, EMBC, and IRMD DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/5/2025EMBCEmbectaquarterly$0.154.51%5/28/20255/28/20256/13/20255/5/2025IRMDiRadimedquarterly$0.171.3%5/20/20255/20/20255/30/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXGNAxoGen0.634.282.65DRTSAlpha Tau Medical0.105.815.81EMBCEmbectaN/A2.481.83IRMDiRadimedN/A8.877.62Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXGNAxoGen80.29%DRTSAlpha Tau Medical2.65%EMBCEmbecta93.83%IRMDiRadimed92.34%Insider OwnershipCompanyInsider OwnershipAXGNAxoGen2.78%DRTSAlpha Tau Medical39.50%EMBCEmbecta0.42%IRMDiRadimed36.80%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXGNAxoGen45045.54 million44.28 millionOptionableDRTSAlpha Tau Medical8084.82 million51.32 millionNo DataEMBCEmbecta2,10058.44 million58.20 millionOptionableIRMDiRadimed11012.72 million8.04 millionOptionableDRTS, AXGN, EMBC, and IRMD HeadlinesRecent News About These CompaniesiRadimed (NASDAQ:IRMD) Stock Price Crosses Above 50-Day Moving Average - Here's WhyJuly 8 at 4:56 AM | marketbeat.comCopeland Capital Management LLC Purchases 14,981 Shares of iRadimed Corporation (NASDAQ:IRMD)June 28, 2025 | marketbeat.comiRadimed Corporation (NASDAQ:IRMD) Shares Sold by Rhumbline AdvisersJune 22, 2025 | marketbeat.comProsperity Wealth Management Inc. Acquires Shares of 6,595 iRadimed Corporation (NASDAQ:IRMD)June 18, 2025 | marketbeat.comNew Strong Sell Stocks for June 12thJune 12, 2025 | zacks.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Purchases 8,774 Shares of Iradimed Corporation (NASDAQ:IRMD)June 11, 2025 | marketbeat.comAre Investors Undervaluing IRADIMED CORPORATION (NASDAQ:IRMD) By 34%?June 2, 2025 | finance.yahoo.comIradimed Corporation Announces FDA Clearance for Next-Generation MRidium® 3870 IV Infusion Pump SystemMay 29, 2025 | quiverquant.comQIRADIMED CORPORATION Announces FDA 510(k) Clearance for MRidium® 3870 Infusion Pump SystemMay 29, 2025 | globenewswire.comIRADIMED CORPORATION (NASDAQ:IRMD) Released Earnings Last Week And Analysts Lifted Their Price Target To US$71.00May 9, 2025 | finance.yahoo.comIradimed Corp Bottom Line Rises In Q1May 6, 2025 | nasdaq.comIRadimed Corporation (NASDAQ:IRMD) Q1 2025 Earnings Call TranscriptMay 6, 2025 | msn.comIradimed Announces Quarterly ResultsMay 5, 2025 | baystreet.caIradimed stock surges as Q1 earnings top estimatesMay 5, 2025 | investing.comIRADIMED CORPORATION (IRMD) Q1 2025 Earnings Call TranscriptMay 5, 2025 | seekingalpha.comIRadimed (IRMD) Lags Q1 Earnings EstimatesMay 5, 2025 | zacks.comIRADIMED CORPORATION Announces First Quarter 2025 Financial ResultsMay 5, 2025 | globenewswire.comCORRECTION -- IRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025April 28, 2025 | globenewswire.comIradimed Corporation to Release 2025 First Quarter Financial Results and Host Conference Call on May 5, 2025April 28, 2025 | quiverquant.comQIRADIMED CORPORATION to Hold First Quarter of 2025 Financial Results Conference Call on May 5, 2025April 28, 2025 | globenewswire.comiRadimed Corporation Common Stock (IRMD)April 24, 2025 | nasdaq.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeDRTS, AXGN, EMBC, and IRMD Company DescriptionsAxoGen NASDAQ:AXGN$11.47 +0.11 (+0.97%) As of 03:09 PM EasternAxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.Alpha Tau Medical NASDAQ:DRTS$3.25 -0.04 (-1.22%) As of 03:06 PM EasternAlpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.Embecta NASDAQ:EMBC$10.32 +0.29 (+2.89%) As of 03:07 PM EasternEmbecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.iRadimed NASDAQ:IRMD$58.94 -0.08 (-0.14%) As of 03:09 PM EasternIRadimed Corp. engages in the development, manufacture, marketing, and distribution of Magnetic Resonance Imaging compatible medical devices. It also provides a non-magnetic Intravenous infusion pump system that is specifically designed for use during MRI procedures. The company was founded by Roger Susi in July 1992 and is headquartered in Winter Springs, FL. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Could Dutch Bros Dethrone Starbucks? Why Investors Are Perking Up Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
